<DOC>
	<DOCNO>NCT02539277</DOCNO>
	<brief_summary>Study topic：A comparative effectiveness research Jinyebaidu granule treat patient acute upper respiratory infection : A double blind , double dummy , randomize , control trial . It post-marketing clinical study evaluate effectiveness , safety cost-effectiveness Jinyebaidu granule treat acute upper respiratory infection . Objectives Study：This study aim evaluate effectiveness , safety cost-effectiveness Jinyebaidu granule treat patient acute upper respiratory infection . Study design：multi-center double-blind , double-dummy , randomize , control trial</brief_summary>
	<brief_title>A Post-marketing Research Jinyebaidu Granule Treating Patients With Acute Upper Respiratory Infection</brief_title>
	<detailed_description>1 . Inclusion criterion - Patients diagnose acute upper respiratory infection . - Patients acute upper respiratory infection diagnose Traditional Chinese Medicine ( TCM ) syndrome wind-heat attacking Lung ( type heat pathogen invade defensive Qi lung ) . - Acute upper respiratory infection onset time le 36 hour . - Patients age 18 70 year old . - Patients agree participate study sign inform consent . 2 . Effectiveness evaluation - TCM symptom : fever , sore throat , cough without expectoration , headache , thirst , change tongue body , tongue coating pulse . - Signs : swollen tonsil , pharyngeal hyperemia . - Body temperature 3 . Safety evaluation - Clinical symptom sign adverse event reaction - Signs : blood pressure , respiration , heart rate , body temperature ; - Routine blood test urine routine ; - Liver function renal function : Alanine transaminase ( ALT ) 、glutamic-oxalacetic transaminease ( AST ) 、serum creatinine ( SCr ) 、urea nitrogen ( BUN ) ; - Incidence electrocardiogram ( ECG ) abnormality . 4 . Cost-effectiveness evaluation cost calculation - The direct medical cost include : registration expense , examination expense , laboratory test expense , Treatment cost , Chinese medicine expense , Chinese herbal medicine expense , western medicine expense ; Indirect medical cost : transportation cost , lose income patient ; Adverse drug reaction cost : cost treatment due adverse drug reaction . - Effect Evaluation : Symptoms sign score , physical examination , incidence complication . 5 . Number participant 600 participant divide two group , experimental group ( n=300 ) control group ( n=300 ) .Each group stratify three layer accord fever , sore throat , fever sore throat . 100 patient include level . 6 . Dose regimen - treatment group : Jinyebaidu granule , blunt , 10g/time , three time day ; Compound Shuanghua granule placebo , blunt , 6g /time , 4 time day . - Control group : Compound double flower particle , blunt , 6g/time , 4 time day ; Jinyebaidu Granule placebo , blunt , 10g/time , three time day . 7 . Course treatment：5 day</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>Inclusion Criteria Patients diagnose acute upper respiratory infection . Patients acute upper respiratory infection diagnose Traditional Chinese Medicine ( TCM ) syndrome windheat attack Lung ( type heat pathogen invade defensive Qi lung ) . Acute upper respiratory infection onset time le 36 hour . Patients age 18 70 year old . Patients agree participate study sign inform consent . Patients diagnose suppurative tonsillitis ( third degree ) , chest Xray imaging show lung inflammation ; White blood cell count 12 E9 , neutrophils 80 % , ALT , AST , BUN , Cr 2 time normal upper limit ; Patients temperature low 37.5 degree centigrade , without sore throat ; Patients temperature high 38.5 degree centigrade ; Patients already receive antibiotic similar drug treatment ; Patients associate severe primary lung disease , lung cancer , tuberculosis , pneumonia infectious disease ; Patients complicate cardiovascular cerebrovascular disease , severe primary disease hematopoietic system , mental illness ; Pregnant lactate woman ; Patients immunodeficiency result organ transplantation , HIV / AIDS , longterm use immunosuppressive agent ; Patients drug allergy ; Patients participate clinical trial , influence outcome evaluation research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>